CAMP report

I. Expression across cell types

Insufficient scRNA-seq data for expression of CAMP at single-cell level.

II. Expression across tissues

sc-RNAseq data

Insufficient scRNA-seq data for expression of CAMP at tissue level.

III. Associated gene sets

GO_0045766Biological processpositive regulation of angiogenesis
GO_0045087Biological processinnate immune response
GO_0019731Biological processantibacterial humoral response
GO_0050829Biological processdefense response to Gram-negative bacterium
GO_0071224Biological processcellular response to peptidoglycan
GO_0071347Biological processcellular response to interleukin-1
GO_0001934Biological processpositive regulation of protein phosphorylation
GO_0071356Biological processcellular response to tumor necrosis factor
GO_1990000Biological processamyloid fibril formation
GO_0050830Biological processdefense response to Gram-positive bacterium
GO_0019835Biological processcytolysis
GO_0042742Biological processdefense response to bacterium
GO_0071222Biological processcellular response to lipopolysaccharide
GO_0008284Biological processpositive regulation of cell population proliferation
GO_0061844Biological processantimicrobial humoral immune response mediated by antimicrobial peptide
GO_0002227Biological processinnate immune response in mucosa
GO_0051873Biological processkilling by host of symbiont cells
GO_0042119Biological processneutrophil activation
GO_0071354Biological processcellular response to interleukin-6
GO_0005615Cellular componentextracellular space
GO_0005576Cellular componentextracellular region
GO_0035580Cellular componentspecific granule lumen
GO_0070062Cellular componentextracellular exosome
GO_0042581Cellular componentspecific granule
GO_1904724Cellular componenttertiary granule lumen
GO_0042995Cellular componentcell projection
GO_0001530Molecular functionlipopolysaccharide binding
GO_0005515Molecular functionprotein binding

IV. Literature review

[source]
Gene nameCAMP
Protein nameCathelicidin antimicrobial peptide (18 kDa cationic antimicrobial protein) (CAP-18) (hCAP-18) [Cleaved into: Antibacterial peptide FALL-39 (FALL-39 peptide antibiotic); Antibacterial peptide LL-37; Antibacterial peptide KR-20; Antibacterial peptide LL-23; Antibacterial peptide LL-29; Antibacterial peptide KS-30; Antibacterial peptide RK-31; Antibacterial peptide FF-33]
Cathelicidin antimicrobial peptide
SynonymsFALL39
hCG_18336
HSD26
CAP18
DescriptionFUNCTION: Antimicrobial protein that is an integral component of the innate immune system . Binds to bacterial lipopolysaccharides (LPS) . Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 . Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin . The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) . .; FUNCTION: [Antibacterial peptide LL-37]: Antimicrobial peptide that is an integral component of the innate immune system . Binds to bacterial lipopolysaccharides (LPS) . Causes membrane permeabilization by forming transmembrane pores (in vitro) . Causes lysis of E.coli . Exhibits antimicrobial activity against Gram-negative bacteria such as P.aeruginosa, S.typhimurium, E.aerogenes, E.coli and P.syringae, Gram-positive bacteria such as L.monocytogenes, S.epidermidis, S.pyogenes and S.aureus, as well as vancomycin-resistant enterococci (in vitro) . Exhibits antimicrobial activity against methicillin-resistant S.aureus, P.mirabilis, and C.albicans in low-salt media, but not in media containing 100 mM NaCl (in vitro) . Forms chiral supramolecular assemblies with quinolone signal (PQS) molecules of P.aeruginosa, which may lead to interference of bacterial quorum signaling and perturbance of bacterial biofilm formation . May form supramolecular fiber-like assemblies on bacterial membranes . Induces cytokine and chemokine production as well as TNF/TNFA and CSF2/GMCSF production in normal human keratinocytes . Exhibits hemolytic activity against red blood cells . .; FUNCTION: [Antibacterial peptide FALL-39]: Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro). .; FUNCTION: [Antibacterial peptide KR-20]: Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition . Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes . .; FUNCTION: [Antibacterial peptide LL-23]: Poorly active (MIC > 150 uM) against E.coli strain K12 . Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 . .; FUNCTION: [Antibacterial peptide LL-29]: Moderately antibacterial. .; FUNCTION: [Antibacterial peptide KS-30]: Moderately antibacterial . Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition . Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes . .; FUNCTION: [Antibacterial peptide RK-31]: Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition . Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes . .; FUNCTION: [Antibacterial peptide FF-33]: Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells. .

FUNCTION: Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro). .

AccessionsJ3KNB4
ENST00000296435.2
P49913
ENST00000652295.2